

*This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.*

Attachment 10  
August 25, 2026

【Therapeutic category】 429 Other antitumor agents

【Non-proprietary name】 Ivosidenib

【Safety measure】 PRECAUTIONS should be revised.

A revised description is underlined.

| Current                                                                               | Revision                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)<br>N/A | 2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)<br><u>Patients receiving the following drugs:</u><br><u>elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate,</u><br><u>darunavir ethanolate/cobicistat, darunavir</u><br><u>ethanolate/cobicistat/emtricitabine/tenofovir alafenamide fumarate,</u><br><u>doravirine, doravirine/islatravir hydrate, dolutegravir sodium/rilpivirine</u><br><u>hydrochloride, bictegravir sodium/emtricitabine/tenofovir alafenamide</u><br><u>fumarate, rilpivirine, rilpivirine hydrochloride, rilpivirine</u><br><u>hydrochloride/emtricitabine/tenofovir alafenamide fumarate, lenacapavir</u><br><u>sodium</u> |
| 10. INTERACTIONS<br>N/A                                                               | 10. INTERACTIONS<br><u>10.1 Contraindications for Co-administration (Do not co-administer with the</u><br><u>following)</u>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

*This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

|  | <u>Drugs</u>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | <u>Signs, symptoms, and treatment</u>                                                      | <u>Mechanism/risk factors</u>                                                              |
|--|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|
|  | <u>Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate</u><br><u>Darunavir ethanolate/cobicistat Darunavir ethanolate/cobicistat/emtricitabine/tenofovir alafenamide fumarate</u><br><u>Doravirine</u><br><u>Doravirine/islatravir hydrate</u><br><u>Dolutegravir sodium/rilpivirine hydrochloride</u><br><u>Bictegravir sodium/emtricitabine/tenofovir alafenamide fumarate</u><br><u>Rilpivirine</u><br><u>Rilpivirine hydrochloride</u><br><u>Rilpivirine hydrochloride/emtricitabine/tenofovir alafenamide</u> | <u>The effects of these drugs may decrease, and resistance to these drugs may develop.</u> | <u>Induction of CYP3A by this drug may reduce the blood concentrations of these drugs.</u> |

*This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

|  |                           |  |  |
|--|---------------------------|--|--|
|  | <u>fumarate</u>           |  |  |
|  | <u>Lenacapavir sodium</u> |  |  |

N/A: Not Applicable. No corresponding description is included in the current PRECAUTIONS.

*This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*